Introduction: Visceral ischemia and reperfusion associated with thoracoabdominal aortic aneurysm (TAAA) repair results in lung injury, which appears to be mediated in part by proinflammatory cytokines. The purpose of this study was to determine the effect of exogenous administration of the antiinflammatory cytokine, recombinant human IL-10 (rhIL-10), on proinflammatory cytokine production (IL-6 and TNFot) and pulmonary neutrophil infiltration after acute visceral ischemia-reperfusion. Methods: Two hours before 25 minutes of supraceliac aortic occlusion, 80 C57BL/6 mice (20 to 22 g) received an intraperitoneal injection ofrhIL-10 (0.2 ~g [n = 20], 2 ~g [n = 20], 5 ~g [n = 25], or 20 ~g [n = 15]), and 16 mice received murine anti-IL-10 IgM 200 I~g. Twenty-five additional mice underwent visceral ischemia-reperfusion without treatment (controls), and 16 mice underwent laparotomy without aortic occlusion (sham).
were not made ischemic. Animal studies have demonstrated that the pulmonary injury after visceral ischemia-reperfusion is in part a result of the production and release of a variety of humoral factors. These humoral factors include proinflammatory cytokines, activated complement, and lipid mediators, including platelet activating factor, prostanoids, leukotrienes, and lipoxinsY s Two proinflammatory cytokines, tumor necrosis factor ~ (TNFc~) and interleukin (IL)-1, have been implicated as early initiators of this'response to visceral ischemia-reperfusion injury. For example, the pathologic changes associated with visceral ischemia-reperfusion can be blocked by pretreatment with inhibitors of these proinflammatory cyto-luly 1997 kines. 8, 9 The clinical importance of this inflammatory response after acute visceral ischemia and reperfusion can be seen after thoracoabdominal aortic aneurysm (TAAA) repair, for which the incidence of pulmonary injury (20% to 47%), altered renal function (20% to 30%), hepatic dysfunction (5% to 15%), multisystem organ dysfimction (5%), and death (5%) are directly related to visceral ischemic time and a proinflammatory response. [10] [11] [12] [13] IL-10 inhibits proinflammatory cytokine production by activated monocytes/macrophages and prevents TNF~ production in acute inflammatory states. 14-17 IL-10 is currently in use in the treatment of patients who have inflammatory bowel disease and rheumatoid arthritis, and potentially could have applications in the treatment of patients who undergo TAAA repair. This study investigates this question in a murine model of acute visceral ischemia similar to that that occurs during TAAA repair and demonstrates that initial lung neutrophil infiltration and TNFo~ production can be inhibited by pretreating mice with recombinant human IL-10 (rhIL-10).
MATERIALS AND METHODS Animal preparation
Female C57BL/6 mice (20 to 22 g; Charles River Breeding Laboratories, Wilmington, Mass.) were anesthetized with 35 mg/kg body weight of intraperitoneal sodium pentobarbital. A laparotomy was then performed and the bowel exteriorized. The supraceliac aorta, the celiac axis, and the superior mesenteric artery were identified, and a microvascular clamp (10 mm) was placed across the supraceliac aorta. Cessation of blood flow to the bowel and visceral organs was confirmed by lack of pulsation in the mesenteric arterial arcades, loss of liver volume, blanching of the liver, and darkening of the spleen. Each mouse was given 50 ml/kg of physiologic saline solution by intraperitoneal injection for crystalloid support, and the abdominal wall was reapproximated to avoid evaporative fluid loss during the period of visceral ischemia.
After 25 minutes of acute visceral ischemia, the abdomen was reopened and the supraceliac crossclamp removed with return ofpulsatile blood flow to the abdominal viscera. Each mouse was then given an additional 50 ml/kg of physiologic saline solution by intraperitoneal injection, and the abdominal incision was closed again. Mice were killed after 2 hours of reperfusion. Two hours ofreperfusion was chosen as the endpoint for these studies on the basis of previous work from our laboratory that demonstrated that maximal murine serum IL-IO levels and peak lung myeloperoxidase (MPO) levels occur 2 hours after visceral ischemia-reperfusion in this model (unpublished data and WelbornS). In those studies, the concentrations of proinflammatory cytokines and lung neutrophil infiltration were evaluated over a I2-hour period after visceral ischemia-reperfusion injury, and peak responses were seen at 2 hours. Blood samples were then obtained via cardiac puncture and serum stored at -70°C for later measurement of murine IL-6, hIL-10, and murine TNFc~ levels. Lungs were also harvested, rinsed in normal saline, flash-frozen, and subsequently stored at -70 ° C for later assessment of neutrophil infiltration. Mice that underwent the identical procedures without placement of the supraceliac clamp were used as sham operative controls.
Experimental groups
Two hours before aortic cross-damping, 80 mice received an intraperitoneal injection of recombinant human IL-IO (0.2 ~g (n = 20), 2 ~g (n = 20), 5 ~g (n = 25), or 20 Ixg (n = 15)/mouse), whereas 16 mice received intraperitoneal purified murine anti-IL-10 immunoglobulin M (IgM; 200 }xg/mouse [10 mg/kg]). Twenty-five additional mice underwent visceral ischemia-reperfusion without treatment with rhlL-10 or anti-IL-10 (controls), and 16 mice underwent sham procedures as previously described (sham).
All protocols were approved by the Institutional Animal Care and Use Committee and the laboratory adheres to the Guiding Principles of Laboratory Animal Care as promulgated by the American Physiologic Sodety.
Determination of pulmonary injury MPO assay. Pulmonary neutrophil sequestration was quantitated by measuring tissue MPO levels. Thawed lung samples were weighed and homogenized in 0.01 mol/L IG-I2PO4 at a ratio of 1:15 weight for volume. After homogenization the resultant supernatant was discarded, and thc pcllct was resuspcnded in cetyltrimethylammonium bromide buffer at a ratio of 1:5 weight for volume. This solution was then incubated at 60 ° C for 2 hours, followed by sonication for 1 minute. The resultant supernatant was collected for mcasurcmcnt of MPO concentrations, which were determined using the H202-dependent oxidation of 3,3'5,5'-tetramethylbenzine, which generates a colorimetric reaction. Spectrophotometric absorbance was read at 650 nm and compared with a linear standard curve with a sensitivity of 0.0625 EU.
Cytokine determinations
Murine IL-6 and human IL-10. Serum cytokine levels were determined as previously described) s Briefly, murine serum IL-6 concentrations were determined by sandwich enzyme-linked immunosorbent assay (ELISA; Endogen, Inc., Boston, Mass.), with a sensitivity of 63 pg/ml. Human IL-10 serum levels were determined using an ELISA that does not cross-react with murine IL-10, with a sensitivity of 3I pg/ml. Serum hIL-10 levels were measured in mice that received 0.2 txg, 2 Ixg, and 5 txg doses of rhlL-I0 to assess absorption from the peritoneal cavity and appearance in the intravascular compartment.
TNFot. Bioactive TNF was measured using the WEHI 164 clone 13 murine fibrosarcoma cell line. ~9 The cells were cultured in 96 well plates and were then exposed either to diluted serum samples or to increasing concentrations of recombinant human TNF~. The cell viability was determined by the reduction Of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) and quantitated at 570 nm. A standard curve was generated with human TNF% and the sensitivity of the assay was 5 pg/ml.
Because of the small volumes of blood obtained from these mice at 2 hours (generally less than 500 txL) and the volumes of plasma sample required for each ELISA (100 Ix/assay), it was not always possible to measure each and every cytokine on every sample. Therefore, the number of subjects for each group is often less than the numbers of mice studied.
Statistical analysis
Statistical analysis was carried out using one-way analysis of variance (ANOVA) for comparison among treatment groups (SigmaStat, Jandel Scientific, San Rafael, CA). In cases in which normality was not obtained (plasma TNF concentrations), a Kruskal-Wallis one-way ANOVA on ranks was performed. A post-hoc comparison among the different groups was undertaken with either a Newman-Keuls multiple range test or Dunn's method. Differences in the frequency of detecting TNF bioactivity were determined using ×2 analysis. Statistical significance was considered achieved if the p value was less than 0.05. All values are presented as the mean _+ standard error of the mean.
RESULTS

Lung MPO
Ischemia-reperfusion injury produced a significant increase in lung MPO levels compared with the sham procedure (Fig. 1 ). In mice with ischemiareperfusion injury, MPO levels were only suppressed in mice that wcrc pretreated with 0.2 v~g, 2 ~g, and 5 txg/mouse of rhIL-10 ( Fig. 1) . MPO values from micc trcatcd with these doses of rhIL-10 were also equivalent to levels from sham treated mice. In contrast, mean MPO levels from micc treated with 20 ~xg/mouse of rhIL-10 were equivalent to valucs from ischemia-reperfusion injury control mice. Mean MPO levels in mice treated with anti-IL-10 were also not different from control mice.
IL-6
Murine IL-6 was detectable in the serum of all mice studied, including those subjected to sham operative procedures. However, ischemia-reperfusion injury significantly increased the plasma IL-6 response at the 2 hour period (Fig. 2) . Administration of IL-10 tended to increase the plasma IL-6 response in all of the groups, although the difference between mean serum IL-6 levels in mice that received rhlL-10 and in the control mice was significant only at the highest dose ofrhIL-10 ( Fig. 2) . Mean IL-6 levels in mice treated with anti-IL-10 (40,698 -+ 11,210) were also significantly higher than ischemia-reperfusion injury controls. 
Human IL-IO
Recombinant human IL-10 was detected in thc serum of all of the mice in which recombinant human IL-10 was administered, whereas no human IL-10 was detected in control or sham mice (Fig. 3) . The mean circulating rhIL-10 level was significantly higher in mice treated with 5 Ixg/mouse ofrhIL-10 (5060 -+ 1151 pg/ml) than in mice that received doses of 0.2 Ixg and 2 b~g/mouse ofrhIL-10 (237 -+ 98 and 773 +_ 63 pg/ml, respectively; Fig. 3 ).
TNFot
TNF~ was detected in the serum of 50% (4 of 8) of the control mice, none (0 of 8) of the mice that received 2 ~g ofrhIL-10, none (0 of 8) of the mice that underwent sham operative procedures, and 75% (6 of 8) of the mice that received anti-IL-10 (p < 0.05 by X 2 analysis). The mice that were pretreated with anti-IL-10 had mean circulating TNFe~ levels (17 + 4 pg/ml) that were statistically higher (by Kruskal-Wallis ANOVA on ranks, p < 0.05) than TNF~ levels from control mice (0 + 0 pg/ml) or from mice that underwent acute visceral ischemiareperfusion alone (10 -+ 4 pg/ml).
DISCUSSION
Morbidity and mortality rates after the repair of TAAAs are significantly higher than after the repair ofinfrarenal abdominal aortic aneurysms. 1°-1s,2° Visceral ischemia and reperfusion during TAAA repair have recently been shown by Harward et al. 18 to produce a significant proinflammatory cytoldne response, and circulating TNF levels appear to be an important determinant of the risk of organ dysfunction after TAAA repair. As opposed to many of the other risk factors for complications after TAAA repair, the proinflammatory cytokine response that is generated by visceral ischemia-reperfusion can be modulated by anticytokine therapy, which might reduce morbidity and mortality rates. This study demonstrates that, in mice, reperfusion of the visceral organs after a period of supraceliac aortic occlusion similar to that that occurs during TAAA repair in human beings produces a distant lung injury that can be attenuated by pretreatrnent with rhIL-10. In addition, production of TNF~x after acute visceral ischemia-reperfusion was suppressed by doses of exogenously administered rhIL-10 that maximally suppressed lung neutrophil infiltration. Conversely, inhibition of endogenous IL-10 activity with anti-IL-10 antibodies exacerbated the IL-6 response after acute visceral ischemia-reperfusion, but did not worsen the degree of lung neutrophil infiltration. This latter finding suggests that an endogenous IL-10 response may attenuate plasma IL-6, but has little direct effect on the early neutrophil infiltration. IL-10 is an immunosuppressive and antiinflam-matory cytokine that is produced by T-cells, natural killer cells, and macrophage/monocyte cell lines. 2L22 Among the many important regulatory properties attributed to IL-10 is the inhibition ofproinflammatory cytokine production in models of acute inflammation. 23 IL-10 has been shown to suppress the production of TNFa, IL-l% IL-lf3, and IL-8 by human monocytes and mouse peritoneal macrophages 14-17 and to limit the mortality rate in a murine model of endotoxemic shock. 24,2s The data presented here indicate that in a murine model the most beneficial effects of exogenously administered rhIL-10 were obtained at the lower doses (i.e., 0.2 txg, 2 b~g, and 5 Ixg/mouse), whereas the highest dose was ineffective at preventing neutrophil infiltration. At the present time, a ready explanation for this observation is lacking. However, IL-10 being a pluripotent cytokinc with immunomodulatory properties in addition to its antiinflammatory actions may well have had an impact on pathways distinct from proinflammatory cytokines like TNFc~. Clearly, Moore and others have implicated lipid mediators (platelet-activating factor [PAF], leukotrienes, prostanoids) in the neutrophil priming and activation that accompanies ischemia-reperfusion injury, 3°26 and the interactions between IL-10, IL-6, prostanoids, and PAF are still unresolved. For example, BiN and colleagues 27 have implicated a role for IL-6 in potentiating PAF-mediated neutrophil priming, 27 and in the present studies, the highest dose oflL-10 significantly increased the plasma IL-6 response.
The cause of the increase in serum IL-6 levels seen with increasing doses ofrhlL-10 in the current study remains unclear. In in vitro studies designed to examine the effect of IL-10 on vascular endothelium, Sironi et al. 28 demonstrated that murine IL-10 induced low levels of IL-6 production and amplified induction of IL-6 by lipopolysaccharide in a murine endothelioma cell line. 28 Therefore, exogenously administered rhlL-10, as well as endogenous murine IL-10 produced in response to visceral ischemiareperfusion, may stimulate endothelial or other cell lines to produce IL-6 in vivo, similar to the in vitro results of Sironi et al.
In a recent clinical trial, Huhn et al. 29 found that patients who received 0.1 to 100 Ixg/kg intravenous rhlL-10 experienced adverse effects (mild flulike syndrome) only at the highest dose and that the half life of rML-10 after intravenous injection was approximately 4 hours. Furthermore, the lowest doses of IL-10 that were not accompanied by any adverse effects were effective at reducing ex vivo proinflammatory responses. These'observations, along with the data from the present study, suggest that pretreating patients with low doses of rhIL-10 will be well tolerated and may limit the initial pulmonary injury and the initial proinflammatory response that are associated with visceral ischemia-reperfusion, and thus possibly reduce pulmonary or other distal organ injury after procedures such as TAAA repair.
The systemic proinflammatory cytokine response is likely only one of the factors involved in pulmonary injury after acute visceral ischemia-reperfusion. Clearly, other humoral factors are involved in this process, including C3a, C5a, PAF, leukotrienes, and other prostanoid products. In reality, proinflammatory cytokines and these other humoral factors are tightly interrelated. Because of this interrelation, it is not clear whcthcr suppression of the cytokine response alone after acute visceral ischemia-reperfusion will result in a clinically significant reduction in pulmonary or other distant organ dysfunction at later time points. The response to visceral ischemia-reperfusion in the current study was only investigated after 2 hours of reperfusion, and exogenous rhIL-10 may only delay rather than limit pulmonary dysfunction associated with acute visceral ischemia. Nevertheless, even the initial reduction in the pulmonary neutrophil sequestration seen in this study in mice treated with exogenous rhlL10 may reduce both the risk of the initial pulmonary injury and later pulmonary injury because of a sccond insult such as bacterial contamination.
